IL313726A - Therapeutic treatment for fragile x-associated disorder - Google Patents
Therapeutic treatment for fragile x-associated disorderInfo
- Publication number
- IL313726A IL313726A IL313726A IL31372624A IL313726A IL 313726 A IL313726 A IL 313726A IL 313726 A IL313726 A IL 313726A IL 31372624 A IL31372624 A IL 31372624A IL 313726 A IL313726 A IL 313726A
- Authority
- IL
- Israel
- Prior art keywords
- fragile
- therapeutic treatment
- associated disorder
- disorder
- therapeutic
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163265989P | 2021-12-23 | 2021-12-23 | |
PCT/US2022/082380 WO2023122800A1 (en) | 2021-12-23 | 2022-12-23 | Therapeutic treatment for fragile x-associated disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
IL313726A true IL313726A (en) | 2024-08-01 |
Family
ID=85199427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL313726A IL313726A (en) | 2021-12-23 | 2022-12-23 | Therapeutic treatment for fragile x-associated disorder |
Country Status (6)
Country | Link |
---|---|
KR (1) | KR20240133725A (en) |
CN (1) | CN118679257A (en) |
AU (1) | AU2022417615A1 (en) |
CA (1) | CA3240593A1 (en) |
IL (1) | IL313726A (en) |
WO (1) | WO2023122800A1 (en) |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5039660A (en) | 1988-03-02 | 1991-08-13 | Endocon, Inc. | Partially fused peptide pellet |
WO1998010090A1 (en) | 1996-09-06 | 1998-03-12 | St. Elizabeth's Medical Center Of Boston, Inc. | Gata-6 transcription factor: compositions and methods |
EP2595664B1 (en) * | 2010-07-19 | 2018-10-17 | Ionis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
US20140212873A1 (en) * | 2011-06-24 | 2014-07-31 | La Trobe University | Treatment and diagnosis of epigenetic disorders and conditions |
RS64622B1 (en) | 2012-05-25 | 2023-10-31 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
BR112015008708A2 (en) | 2012-10-23 | 2017-09-26 | Toolgen Inc | a target DNA cleavage composition comprising a target DNA specific guide and nucleic acid encoding cas protein or cas protein and use thereof |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
DK2898075T3 (en) | 2012-12-12 | 2016-06-27 | Broad Inst Inc | CONSTRUCTION AND OPTIMIZATION OF IMPROVED SYSTEMS, PROCEDURES AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION |
PT2771468E (en) | 2012-12-12 | 2015-06-02 | Harvard College | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
BR122021008308B1 (en) | 2012-12-12 | 2022-12-27 | The Broad Institute, Inc. | CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION |
PL2931898T3 (en) | 2012-12-12 | 2016-09-30 | Le Cong | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
WO2015023937A1 (en) * | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Heterochromatin forming non-coding rnas |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
WO2018170290A1 (en) * | 2017-03-15 | 2018-09-20 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fmr1 expression |
GB2574243A (en) * | 2018-05-31 | 2019-12-04 | The Govening Council Of The Univ Of Toronto | Adeno-associated viral vector-mediated gene therapy for treating fragile X-associated disorders |
CA3130854A1 (en) * | 2019-02-26 | 2020-09-03 | Nogra Pharma Limited | Fragile x mental retardation protein interfering oligonucleotides and methods of using same |
AU2020269398A1 (en) * | 2019-05-07 | 2021-11-25 | Ecole Polytechnique Federale De Lausanne (Epfl) | FMRP and cancer treatment |
CN113151406B (en) * | 2021-03-25 | 2022-06-21 | 深圳会众生物技术有限公司 | FMR1 gene CGG repetition number and methylation detection kit and detection method |
-
2022
- 2022-12-23 KR KR1020247024797A patent/KR20240133725A/en unknown
- 2022-12-23 CN CN202280089598.9A patent/CN118679257A/en active Pending
- 2022-12-23 IL IL313726A patent/IL313726A/en unknown
- 2022-12-23 AU AU2022417615A patent/AU2022417615A1/en active Pending
- 2022-12-23 CA CA3240593A patent/CA3240593A1/en active Pending
- 2022-12-23 WO PCT/US2022/082380 patent/WO2023122800A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN118679257A (en) | 2024-09-20 |
WO2023122800A1 (en) | 2023-06-29 |
CA3240593A1 (en) | 2023-06-29 |
AU2022417615A1 (en) | 2024-06-27 |
KR20240133725A (en) | 2024-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL307964A (en) | Combination therapy for cancer treatment | |
GB202001980D0 (en) | Therapeutic mentods | |
GB202005852D0 (en) | Therapeutic compounds | |
GB202006960D0 (en) | Therapeutic | |
IL313726A (en) | Therapeutic treatment for fragile x-associated disorder | |
GB2616591B (en) | Surface treatment system | |
GB202005863D0 (en) | Therapeutic compounds | |
GB202001182D0 (en) | Treatment for chronic pain | |
GB202313014D0 (en) | Novel therapeutic treatment | |
GB202218510D0 (en) | Novel therapeutic treatment | |
GB202102957D0 (en) | Therapeutic intervention | |
CA204247S (en) | Spa treatment tray | |
GB202016955D0 (en) | Therapeutic treatments | |
GB202006659D0 (en) | Therapeutic treatments | |
GB202110329D0 (en) | Therapeutic | |
IL311229A (en) | Triple-agent therapy for cancer treatment | |
GB202316239D0 (en) | Therapeutic combination | |
GB202319954D0 (en) | Treatment | |
GB202319658D0 (en) | Treatment | |
GB202319443D0 (en) | Treatment | |
GB202318845D0 (en) | Treatment | |
GB202311007D0 (en) | Treatment | |
EP4121166C0 (en) | Therapeutic treatment of chromatinopathies | |
GB202304853D0 (en) | Treatment | |
GB202218460D0 (en) | Treatment |